Please provide your email address to receive an email when new articles are posted on . Cannabidiol treatment was associated with median reduction of 67% to 99% in focal aware seizures. All ...

Research on epilepsy during the early 20 th century led to the discovery of treatments for symptomatic seizures, such as bromide, phenobarbital, and phenytoin. Furthermore, the development of the ...

PHILADELPHIA — New open-label data from the expanded-access treatment program involving the cannabidiol Epidiolex (GW Pharma) show the median reduction in frequency of convulsive seizures after 3 ...

Seizures are difficult to control in the Dravet syndrome, a rare genetic form of epileptic encephalopathy primarily due to loss-of-function mutations in the SCN1A gene. Interest in cannabidiol for the ...

This transcript has been edited for clarity. Andrew N. Wilner, MD: Welcome to Medscape. I'm your host, Dr Andrew Wilner, reporting on the annual American Epilepsy Society meeting. With me today is my ...

Please provide your email address to receive an email when new articles are posted on . LOS ANGELES — Treatment with cannabidiol led to improved seizure and nonseizure outcomes in patients with ...

A study reveals a previously unknown way in which cannabidiol (CBD), a substance found in cannabis, reduces seizures in many treatment-resistant forms of pediatric epilepsy. Led by researchers at NYU ...

Trial is the first randomized, controlled clinical trial evaluating cannabidiol to treat children and adolescents living with a developmental and epileptic encephalopathy known as Epilepsy with ...

– Age-range for all EPIDIOLEX indications expanded to include patients one year of age and older – – Third indication approved for EPIDIOLEX, the only FDA-approved Cannabidiol (CBD) medicine – ...

GW also welcomes the positive guideline recommendation for Sativex® (nabiximols) for the treatment of spasticity due to multiple sclerosis as part of NICE’s evaluation of cannabis-based medicinal ...